{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:49:14Z","timestamp":1781207354612,"version":"3.54.1"},"reference-count":20,"publisher":"Hogrefe Publishing Group","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2023,3]]},"abstract":" Zusammenfassung. Kombinierte hormonelle Kontrazeptiva (CHC) sind eine wertvolle und \u00e4usserst wirksame Option bei der Beratung von Frauen mit Wunsch nach Verh\u00fctung. In der Schweiz verf\u00fcgbare Anwendungsformen sind \u00abPillen\u00bb bzw. kombinierte orale Kontrazeptiva (KOK), Vaginalringe und transdermale Pflaster. Alle Pr\u00e4parate enthalten eine \u00d6strogen- und eine Gestagenkomponente. Als \u00d6strogenkomponente wird in den verschiedenen Produkten vorwiegend das synthetisch hergestellte Ethinylestradiol (EE) verwendet, wobei mittlerweile auch KOK verf\u00fcgbar sind, die nat\u00fcrlich vorkommende \u00d6strogene wie Estradiol (E2) und Estetrol (E4) enthalten. F\u00fcr die Gestagenkomponente steht eine Reihe an Gelbk\u00f6rperhormonen zur Verf\u00fcgung, die es aufgrund ihrer unterschiedlichen Partialwirkungen erm\u00f6glichen, ein f\u00fcr die Anwenderin \u00abmassgeschneidertes\u00bb Produkt zu verschreiben. Bei der Verschreibung von Kombinationspr\u00e4paraten ist jedoch auch immer das individuelle Thromboembolie (TE)-Risiko zu beachten. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003993","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T07:05:46Z","timestamp":1678863946000},"page":"205-210","source":"Crossref","is-referenced-by-count":2,"title":["Kombinierte hormonelle Kontrazeption \u2013 welches Pr\u00e4parat f\u00fcr welche Indikation?"],"prefix":"10.1024","volume":"112","author":[{"given":"Philipp","family":"Quaas","sequence":"first","affiliation":[{"name":"Frauenklinik, Universit\u00e4tsspital Basel, Universit\u00e4t Basel, Basel, Schweiz"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"101","reference":[{"key":"c1","unstructured":"Baumgartner L . Orale Kontrazeption \u2013 ein Leitfaden\n f\u00fcr die aktuelle Verh\u00fctungsberatung.\n 2022. Available from: https:\/\/www.cme-kurs.de\/kurse\/orale-kontrazeption-leitfaden-aktuelle-verhuetungsberatung\/;\n letzter Zugriff: 14.12.2022."},{"key":"c2","unstructured":"Bombas T , \n Sedlecki K , \n Roumen F , \n Lete-Lasa I , \n Merki G . The European Society of Contraception and\n Reproductive Health (ESCRH) \u2013 Training Improvement\n Programme. 2022. https:\/\/escrh.eu\/education\/training-improvement-programme\/ttt-tool-sessions-eng\/;\n letzter Zugriff: 14.12.2022."},{"key":"c3","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0b013e328355871d"},{"key":"c4","doi-asserted-by":"publisher","DOI":"10.2147\/OAJC.S179673"},{"key":"c5","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2022.2093850"},{"key":"c6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700732"},{"key":"c7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3609"},{"key":"c8","unstructured":"Surbek D , \n Merki-Feld GS , \n Tschudin S , \n Stute P , \n Wunder D . Expertenbrief zum Thromboembolierisiko unter\n hormonaler Kontrazeption. Schweizerische\n Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe\n (SGGG); 2001."},{"key":"c9","unstructured":"World Health Organization (WHO). Medical eligibility\n criteria for contraceptive use.\n 2009;"},{"key":"c10","unstructured":"Merki-Feld GS , \n Bitzer J , \n Seydoux J , \n Birkh\u00e4user M . Handout f\u00fcr \u00c4rzte zur Verschreibung\n kombinierter hormonaler Kontrazeptiva (CHC).\n Schweizerische Gesellschaft f\u00fcr Gyn\u00e4kologie und\n Geburtshilfe (SGGG). Basel;\n Birkh\u00e4user:\n 2013."},{"key":"c11","unstructured":"Merki-Feld GS , \n Bitzer J , \n Seydoux J , \n Birkh\u00e4user M . Checkliste CHC f\u00fcr Erst-oder\n Neuverschreibung. Schweizerische Gesellschaft\n f\u00fcr Gyn\u00e4kologie und Geburtshilfe (SGGG).\n Birkh\u00e4user; 2013"},{"key":"c12","volume":"6","author":"Merki-Feld GS","year":"2013","journal-title":"Schweizerische Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (SGGG)"},{"key":"c13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-1047"},{"key":"c14","volume":"5","author":"Birkh\u00e4user M","year":"2013","journal-title":"Gyn\u00e4kologie"},{"key":"c15","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.03.018"},{"key":"c16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","author":"van den Heuvel MW","year":"2005","journal-title":"Contraception"},{"key":"c17","unstructured":"R\u00f6mer T . Hormonal oral contraception \u2013 Which\n preparation for which patient? Gynakologische Endokrinol.\n 2021."},{"key":"c18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.704488"},{"key":"c19","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05340-4"},{"key":"c20","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-020-01080-9"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T07:06:23Z","timestamp":1678863983000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1024\/1661-8157\/a003993"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003993","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}